cyclophilin


Also found in: Medical, Acronyms, Wikipedia.

cyclophilin

[‚sī·kə′fil·ən]
(biochemistry)
An abundant cytoplasmic protein that catalyzes cis-trans isomerizations; it has a high affinity for the immunosuppressive drug cyclosporin A.
References in periodicals archive ?
The team found that ApoE4 makes it more likely that cyclophilin A will accumulate in large amounts in cells that help maintain the blood-brain barrier, a network of tightly bound cells that line the insides of blood vessels in the brain and carefully regulates what substances are allowed to enter and exit brain tissue.
Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death.
About SCY-635 and SCYNEXIS' Cyclophilin Inhibitor Platform SCY-635 represents a new class of therapeutic agents for the treatment of HCV infection.
The results of our bilirubin transport studies demonstrate a potentially important differentiation among candidates within the cyclophilin class of drugs and further position SCY-635 as the leading cyclophilin inhibitor in development for the treatment of HCV," said Yves Ribeill, PhD, Chief Executive Officer of SCYNEXIS.
NeuroVive's products are based on cyclosporin-A and cyclosporine derivatives acting as cyclophilin inhibitors for disease prevention and control through mitochondrial protection.
today announced that multiple abstracts related to the Company's cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010.
These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes - protease (partnered with Abbott), NS5A (partnered with Novartis) and nucleotide polymerase - as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin.
Subsequent real-time PCR quantification of survivin mRNA and, for normalization of expression, of the housekeeping gene cyclophilin A was performed as described previously in detail (13).
SCY-635 is a novel cyclophilin inhibitor and represents a new pharmacological class of inhibitors of HCV replication.
Poster #1895 - "EDP-546, a Potent and Novel Cyclophilin Inhibitor with Favorable Preclinical Pharmacokinetic and Safety Profiles" L.
Along with immunomodulators, long acting/oral interferons, and direct acting anti-viral therapies, new compounds represented by several other drug categories, including Polymerase/Protease Inhibitors, MicroRNA, TLR9 agonists, NS5A Inhibitors, Cyclophilin inhibitors, A3AR Agonists, and vaccines among others, would be successfully developed to expand the scope of HCV treatment.